Navigation Links
Researchers identify new cell targets for preventing growth of breast and other tumors
Date:4/23/2008

CHAPEL HILL Researchers at the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill have discovered new targets for cancer treatment aimed at blocking a key step in tumor progression.

This step the creation of new blood vessels enables tumors to grow out of control and ultimately spread cancer to other parts of the body.

Targeting blood vessel formation, or angiogenesis, promises to be less toxic than the standard chemotherapy approach that kills cancer cells and normal cells alike. The new tactic has been shown by others to be successful in the treatment of breast cancer and colon cancer with the drug bevacizumab (commercially known as Avastin), which inhibits an important player in angiogenesis, a protein called vascular endothelial growth factor (VEGF).

There is a large amount of data that shows if you block angiogenesis, you can block tumor growth, said Dr. Nancy Klauber-DeMore, associate professor of surgery in the UNC School of Medicine and senior author on the study. But VEGF is not responsible for all of angiogenesis. We wanted to identify more targets for this therapeutic approach.

The most exciting aspect of this study is that we now have a very large list of potential targets that we will continue to work on for at least the next decade, Klauber-DeMore said.

A report of the study appeared online this month in the American Journal of Pathology. It will be published in the May 2008 print edition of the journal.

Angiogenesis only occurs normally in a few instances, such as wound healing, female reproduction and fetal development. But it also plays an important role in the growth and spread of cancer. New blood vessels provide essential nourishment to cancer cells, allowing them to grow, travel to other parts of the body and form new cancers.

Because tumors cannot grow or spread without the formation of new blood vessels, Klauber-DeMore sought new targets that are produced in excess (overexpressed) on tumor blood vessels. The hope is that by identifying proteins on these vessels, new drugs may be developed that block these proteins and put a stop to tumor blood vessel growth.

In a technique that took three years to perfect, the UNC researchers microdissected individual vascular cells from frozen sections of five cancerous and five normal breast tissue samples. They scanned the activity of thousands of genes in the isolated cells and then compared the gene activity between the tumor and normal vascular samples. They found 1,176 genes that differed in activity or expression between the two cell populations. Of these, 55 genes were overexpressed more than four-fold in blood vessels from breast cancer.

Because proteins that either lie on the cell surface or are secreted from the cell are the easiest targets for drug development, the researchers searched a database to pinpoint the likely cellular location of the proteins encoded by the candidate genes. They found that seven of the genes encoded membrane or secreted proteins. Four of these namely FAP, SFRP2, JAK3 and SMPD3 had not just increased gene expression, but also increased protein expression in breast tumor vessels, and thus could be good targets for the development of novel cancer therapies.

The researchers need to do further research to accurately define whether these proteins induce angiogenesis, Klauber-DeMore said. They can then design new compounds and test existing ones to see if they inhibit tumor growth.

Weve only looked at seven out of a list of 55 potential targets, Klauber-DeMore said. This work points us in the direction we need to go to develop the next generation of angiogenesis inhibitors.

Klauber-DeMore said that other researchers, led by George Coukos at Fox Chase Cancer Center, are trying the same approach with ovarian cancer, suggesting that this strategy may be applicable to many different tumor types.


'/>"/>

Contact: Dianne Shaw
dgs@med.unc.edu
919-966-5905
University of North Carolina at Chapel Hill
Source:Eurekalert

Related medicine news :

1. Melanoma lurks in larger skin lesions, NYU researchers find
2. Reduced Funds for Cancer is Cost of Iraq, Say Ex-White House Aide, Cancer Researchers
3. MU researchers reveal communication tactics used by sexual predators to entrap children
4. Penn researchers find potential in yeast for selecting Lou Gehrigs disease drugs
5. MU researchers find clue to cataract formation
6. Researchers evaluating food allergy treatment
7. U of M researchers identify process that may help treat Parkinsons, spinal cord injuries
8. OHSU Cancer Institute researchers discover key gene involvement in cancer development
9. Combining liver cancer treatments doubles survival rates, UVA researchers find
10. Leading HIV researchers to collaborate on vaccine development
11. Georgetown researchers find stem cell marker controls 2 key cancer pathways
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... The OSHA Training ... Institute Education Center headquartered in Northern California, has issued an important reminder to ... their worksites. Employers with workers exposed to high temperatures should establish a ...
(Date:6/27/2016)... ... ... "FCPX editors can now reveal their media with growing colorful split screen ... - CEO of Pixel Film Studios. , ProSlice Color brings the split screens ... reveal the media of their split screens with growing colorful panels. , ProSlice Color ...
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/27/2016)... ... June 27, 2016 , ... ePAY ... partnership with Connance, a healthcare industry leader providing predictive analytics to optimize ... combine to provide health systems, hospitals and ambulatory surgical centers with dramatic ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... cutting edge technology to revolutionize the emergency ambulance transport experience for the millions ... aware of how Uber has disrupted the taxi industry through the use of ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/26/2016)... 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) ... measures required to build a strong and stable market ... listed on the OTC Markets-pink current trading platform. ... "We are seeing an anomaly in market trading activities ... by the Company, but shareholders and market players as ...
Breaking Medicine Technology: